antipyrine has been researched along with Infarction, Middle Cerebral Artery in 41 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia." | 7.80 | Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. ( Johshita, H; Miyazaki, H; Okamura, K; Shiokawa, Y; Tsubokawa, T, 2014) |
| "Edaravone is a novel free radical scavenger that is clinically employed in patients with acute cerebral infarction." | 7.78 | Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. ( Chen, X; Gao, M; Lei, S; Li, L; Li, W; Li, X; Liu, Y; Lu, H; Wang, N; Zhang, P; Zheng, J, 2012) |
| "Treatment with edaravone (3 and 10 mg/kg) significantly diminished the cerebral infarct, oedema volume and improved functional recovery of neurological deficits." | 5.38 | Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012) |
| "Montelukast was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and edaravone were used as controls." | 5.33 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005) |
| "Edaravone has been widely used in the treatment of acute ischemic stroke." | 4.12 | Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats. ( Luo, HY; Parikh, A; Xiong, YX; Ye, QY; Zhao, LQ; Zhou, XF, 2022) |
| "Edaravone attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia." | 3.80 | Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. ( Johshita, H; Miyazaki, H; Okamura, K; Shiokawa, Y; Tsubokawa, T, 2014) |
| "Edaravone is a novel free radical scavenger that is clinically employed in patients with acute cerebral infarction." | 3.78 | Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. ( Chen, X; Gao, M; Lei, S; Li, L; Li, W; Li, X; Liu, Y; Lu, H; Wang, N; Zhang, P; Zheng, J, 2012) |
| "We demonstrate that edaravone inhibits rtPA-induced cerebral hemorrhage in the ischemic brain of rats via the inhibition of MMP-9 expression in vivo, which is substantiated by inhibition of MMP-9 expression and NF-kappaB activation in HBECs." | 3.75 | Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. ( Kinouchi, T; Kitazato, KT; Nagahiro, S; Shimada, K; Tada, Y; Uno, M; Yagi, K, 2009) |
| "The effects of ozagrel (CAS 82571-53-7), a thromboxane A2-synthetase inhibitor, and norphenazone (CAS 89-25-8), a free-radical scavenger, on cerebral infarction were assessed using the suture-induced middle cerebral artery occlusion (MCAO) model and a microthrombosis model." | 3.72 | Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger. ( Ichikawa, K; Imamura, T; Kiguchi, S; Kobayashi, K; Kojima, M; Yamazaki, Y, 2003) |
| "Rat transient middle cerebral artery occlusion (MCAO) model was established." | 1.43 | Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model. ( Chen, J; Ding, WS; Ding, XS; Liu, XF; Shen, HC; Shen, LH; Sheng, YF; Ye, M, 2016) |
| "SD rats were subjected to 2-h-middle cerebral artery occlusion (MCAO)." | 1.42 | The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats. ( Hua, K; Huang, ZJ; Ji, H; Li, TT; Sheng, X; Wang, LN; Zhang, YH, 2015) |
| " Most importantly, 3d possessed a very high absolute bioavailability and was rapidly distributed in brain tissue to keep high plasma drug concentration for the treatment of ischemic strokes." | 1.42 | Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent. ( Lan, Z; Lei, M; Li, J; Liang, Z; Xu, W; Xu, X; Zhang, X; Zhao, C, 2015) |
| "Transient middle cerebral artery occlusion (tMCAO) in rodents is one of the most widely utilized models in experimental stroke studies on focal cerebral ischemia." | 1.40 | The middle cerebral artery occlusion model of transient focal cerebral ischemia. ( Liu, F; McCullough, LD, 2014) |
| "In vivo, both Edaravone and Scutellarin markedly reduced the infarct cerebral tissue area with the latter drug being more effective with the dosage used; furthermore, when used in combination the reduction was more substantial." | 1.40 | Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia. ( Ling, EA; Rangarajan, P; Wu, C; Yuan, Y; Zha, H, 2014) |
| "Treatment with edaravone (3 and 10 mg/kg) significantly diminished the cerebral infarct, oedema volume and improved functional recovery of neurological deficits." | 1.38 | Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012) |
| "In vivo, rat transient middle cerebral artery occlusion (MCAO) model was established." | 1.38 | Protective effects of MCI-186 on transplantation of bone marrow stromal cells in rat ischemic stroke model. ( Ding, XS; Gu, XS; Han, Q; Huang, H; Huang, HF; Liu, XF; Shen, LH; Wu, EB; Ye, M; Zhang, C, 2012) |
| "Oral montelukast (0." | 1.37 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. ( Fang, SH; Shi, WZ; Wei, EQ; Zhang, YM; Zhao, R, 2011) |
| "To validate this new model of reperfusion injury, we used two well characterized neuroprotectants, estrogen and edaravone." | 1.36 | A novel rodent model of reperfusion injury following occlusion of the middle cerebral artery. ( Connell, BJ; Saleh, TM, 2010) |
| "Mice subjected to 2-h filamental middle cerebral artery occlusion were treated with NBO (95% O2, during the ischemia) alone, with edaravone (1." | 1.35 | Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice. ( Hara, H; Iwama, T; Nonaka, Y; Shimazawa, M; Yoshimura, S, 2008) |
| "Edaravone treatment significantly reduced the lesion volume and improved the neurological score." | 1.35 | Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model. ( Fujii, M; Fujisawa, H; Gondo, T; Izuma, H; Kajiwara, K; Kato, S; Nomura, S; Oka, F; Suzuki, M; Uozumi, K, 2009) |
| "Treatment with serofendic acid (1-30 nmol) reduced the infarct volume in a dose-dependent manner." | 1.35 | Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in rats. ( Akaike, A; Katsuki, H; Kume, T; Nakamura, T; Niidome, T; Sugimoto, H, 2008) |
| "Montelukast was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and edaravone were used as controls." | 1.33 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (39.02) | 29.6817 |
| 2010's | 23 (56.10) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, LQ | 1 |
| Parikh, A | 1 |
| Xiong, YX | 1 |
| Ye, QY | 1 |
| Zhou, XF | 1 |
| Luo, HY | 1 |
| Shi, X | 1 |
| Ohta, Y | 2 |
| Nakano, Y | 1 |
| Liu, X | 3 |
| Tadokoro, K | 1 |
| Feng, T | 1 |
| Nomura, E | 1 |
| Tsunoda, K | 1 |
| Sasaki, R | 1 |
| Matsumoto, N | 1 |
| Osakada, Y | 1 |
| Bian, Y | 1 |
| Bian, Z | 1 |
| Omote, Y | 3 |
| Takemoto, M | 1 |
| Hishikawa, N | 1 |
| Yamashita, T | 3 |
| Abe, K | 5 |
| Tian, F | 4 |
| Deguchi, K | 3 |
| Kawai, H | 2 |
| Okamura, K | 1 |
| Tsubokawa, T | 1 |
| Johshita, H | 1 |
| Miyazaki, H | 1 |
| Shiokawa, Y | 1 |
| Liu, F | 1 |
| McCullough, LD | 1 |
| Dohare, P | 1 |
| Hyzinski-García, MC | 1 |
| Vipani, A | 1 |
| Bowens, NH | 1 |
| Nalwalk, JW | 1 |
| Feustel, PJ | 1 |
| Keller, RW | 1 |
| Jourd'heuil, D | 1 |
| Mongin, AA | 1 |
| Yuan, Y | 1 |
| Zha, H | 1 |
| Rangarajan, P | 1 |
| Ling, EA | 1 |
| Wu, C | 1 |
| Endepols, H | 1 |
| Mertgens, H | 1 |
| Backes, H | 1 |
| Himmelreich, U | 1 |
| Neumaier, B | 1 |
| Graf, R | 1 |
| Mies, G | 1 |
| Aoyama, Y | 1 |
| Ohta, S | 1 |
| Sakaki, S | 1 |
| Nishizawa, S | 1 |
| Fujita, T | 1 |
| Hua, K | 1 |
| Sheng, X | 1 |
| Li, TT | 1 |
| Wang, LN | 1 |
| Zhang, YH | 1 |
| Huang, ZJ | 1 |
| Ji, H | 1 |
| Lan, Z | 1 |
| Xu, X | 1 |
| Xu, W | 1 |
| Li, J | 1 |
| Liang, Z | 1 |
| Zhang, X | 1 |
| Lei, M | 1 |
| Zhao, C | 1 |
| Hu, H | 1 |
| Sun, Xo | 1 |
| Zhang, H | 2 |
| Liu, Q | 1 |
| Tan, W | 1 |
| Shen, LH | 2 |
| Chen, J | 1 |
| Shen, HC | 1 |
| Ye, M | 2 |
| Liu, XF | 2 |
| Ding, WS | 1 |
| Sheng, YF | 1 |
| Ding, XS | 2 |
| Nonaka, Y | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Okanishi, T | 1 |
| Kondo, A | 1 |
| Inoue, T | 1 |
| Maegaki, Y | 1 |
| Ohno, K | 1 |
| Togari, H | 1 |
| Yagi, K | 1 |
| Kitazato, KT | 1 |
| Uno, M | 1 |
| Tada, Y | 1 |
| Kinouchi, T | 1 |
| Shimada, K | 1 |
| Nagahiro, S | 1 |
| Kamiya, T | 1 |
| Inaba, T | 1 |
| Shang, J | 2 |
| Miyazaki, K | 2 |
| Ohtsuka, A | 1 |
| Katayama, Y | 1 |
| Tanahashi, N | 1 |
| Oka, F | 1 |
| Fujisawa, H | 1 |
| Nomura, S | 1 |
| Kajiwara, K | 1 |
| Kato, S | 1 |
| Fujii, M | 1 |
| Izuma, H | 1 |
| Uozumi, K | 1 |
| Gondo, T | 1 |
| Suzuki, M | 1 |
| Hughes, JL | 1 |
| Beech, JS | 1 |
| Jones, PS | 1 |
| Wang, D | 1 |
| Menon, DK | 1 |
| Baron, JC | 1 |
| Yamamoto, Y | 1 |
| Yanagisawa, M | 1 |
| Tak, NW | 1 |
| Watanabe, K | 1 |
| Takahashi, C | 1 |
| Fujisawa, A | 1 |
| Kashiba, M | 1 |
| Tanaka, M | 1 |
| Chi, OZ | 2 |
| Hunter, C | 2 |
| Chokshi, SK | 1 |
| Weiss, HR | 2 |
| Connell, BJ | 1 |
| Saleh, TM | 1 |
| Chi, Y | 1 |
| Zhao, R | 1 |
| Shi, WZ | 1 |
| Zhang, YM | 1 |
| Fang, SH | 1 |
| Wei, EQ | 2 |
| Liu, N | 2 |
| Nishi, H | 1 |
| Srinivasan, K | 1 |
| Sharma, SS | 1 |
| Zhang, P | 1 |
| Li, W | 1 |
| Li, L | 1 |
| Wang, N | 1 |
| Li, X | 1 |
| Gao, M | 1 |
| Zheng, J | 1 |
| Lei, S | 1 |
| Chen, X | 1 |
| Lu, H | 1 |
| Liu, Y | 1 |
| Liu, W | 1 |
| Kono, S | 1 |
| Yunoki, T | 1 |
| Deguchi, S | 1 |
| Lu, RY | 1 |
| Luo, DF | 1 |
| Xiao, SH | 1 |
| Yang, LH | 1 |
| Zhao, J | 1 |
| Ji, EN | 1 |
| Tao, EX | 1 |
| Xing, YG | 1 |
| Zhu, FY | 1 |
| Luan, P | 1 |
| Liu, J | 1 |
| Ahmad, A | 1 |
| Khan, MM | 1 |
| Javed, H | 1 |
| Raza, SS | 1 |
| Ishrat, T | 1 |
| Khan, MB | 1 |
| Safhi, MM | 1 |
| Islam, F | 1 |
| Han, Q | 1 |
| Zhang, C | 1 |
| Huang, H | 1 |
| Wu, EB | 1 |
| Huang, HF | 1 |
| Gu, XS | 1 |
| Imamura, T | 1 |
| Kiguchi, S | 1 |
| Kobayashi, K | 1 |
| Ichikawa, K | 1 |
| Yamazaki, Y | 1 |
| Kojima, M | 1 |
| McColl, BW | 1 |
| Carswell, HV | 1 |
| McCulloch, J | 1 |
| Horsburgh, K | 1 |
| Yu, GL | 1 |
| Zhang, SH | 1 |
| Xu, HM | 1 |
| Chu, LS | 1 |
| Zhang, WP | 1 |
| Zhang, Q | 1 |
| Chen, Z | 1 |
| Mei, RH | 1 |
| Zhao, MH | 1 |
| Shichinohe, H | 1 |
| Kuroda, S | 1 |
| Yasuda, H | 1 |
| Ishikawa, T | 1 |
| Iwai, M | 1 |
| Horiuchi, M | 1 |
| Iwasaki, Y | 1 |
| Inoue, A | 1 |
| Fukumoto, SY | 1 |
| Kumon, Y | 1 |
| Watanabe, H | 1 |
| Fumoto, N | 1 |
| Oda, S | 1 |
| Ohue, S | 1 |
| Ohnishi, T | 1 |
| Zhang, W | 1 |
| Koerner, IP | 1 |
| Noppens, R | 1 |
| Grafe, M | 1 |
| Tsai, HJ | 1 |
| Morisseau, C | 1 |
| Luria, A | 1 |
| Hammock, BD | 1 |
| Falck, JR | 1 |
| Alkayed, NJ | 1 |
| Takizawa, S | 1 |
| Izuhara, Y | 1 |
| Kitao, Y | 1 |
| Hori, O | 1 |
| Ogawa, S | 1 |
| Morita, Y | 1 |
| Takagi, S | 1 |
| van Ypersele de Strihou, C | 1 |
| Miyata, T | 1 |
| Nakamura, T | 1 |
| Kume, T | 1 |
| Katsuki, H | 1 |
| Niidome, T | 1 |
| Sugimoto, H | 1 |
| Akaike, A | 1 |
| Kilic, E | 1 |
| Bähr, M | 1 |
| Hermann, DM | 1 |
1 review available for antipyrine and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
[Thrombolysis by intravenous tissue plasminogen activator (t-PA)--current status and future direction].
Topics: Antipyrine; Aortic Aneurysm, Thoracic; Aortic Dissection; Edaravone; Free Radical Scavengers; Humans | 2009 |
40 other studies available for antipyrine and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats.
Topics: Animals; Antipyrine; Edaravone; Free Radical Scavengers; Infarction, Middle Cerebral Artery; Ischemi | 2022 |
Neuroprotective effect of CuATSM in mice stroke model by ameliorating oxidative stress.
Topics: Animals; Antipyrine; Brain Ischemia; Infarction, Middle Cerebral Artery; Mice; Neuroprotective Agent | 2021 |
In vivo optical imaging correlates with improvement of cerebral ischemia treated by intravenous bone marrow stromal cells (BMSCs) and edaravone.
Topics: Animals; Antipyrine; Bone Marrow Cells; Bone Marrow Transplantation; Brain; Brain Ischemia; Disease | 2013 |
Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia.
Topics: Animals; Antipyrine; Blood Glucose; Brain; Cerebral Hemorrhage; Cerebral Infarction; Edaravone; Free | 2014 |
The middle cerebral artery occlusion model of transient focal cerebral ischemia.
Topics: Animals; Antipyrine; Cerebral Cortex; Cerebrovascular Circulation; Disease Models, Animal; Infarctio | 2014 |
The neuroprotective properties of the superoxide dismutase mimetic tempol correlate with its ability to reduce pathological glutamate release in a rodent model of stroke.
Topics: Alanine; Animals; Antipyrine; Astrocytes; Brain; Cells, Cultured; Cyclic N-Oxides; Drug Evaluation, | 2014 |
Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.
Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Apigenin; Brain; Brain Ischemia; Cell Count; Cell Lin | 2014 |
Longitudinal assessment of infarct progression, brain metabolism and behavior following anterior cerebral artery occlusion in rats.
Topics: Animals; Anterior Cerebral Artery; Antipyrine; Autoradiography; Brain; Brain Infarction; Cerebrovasc | 2015 |
[Case of spontaneous cervical internal carotid artery dissection with embolic stroke after a job-change].
Topics: Antipyrine; Arginine; Carotid Artery, Internal, Dissection; Diagnosis, Differential; Edaravone; Huma | 2014 |
The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats.
Topics: Animals; Antioxidants; Antipyrine; Apoptosis; Benzofurans; Brain; Edaravone; Infarction, Middle Cere | 2015 |
Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent.
Topics: Animals; Antioxidants; Antipyrine; Behavior, Animal; Benzofurans; Biological Availability; Brain; Ca | 2015 |
Neuroprotective Effects of Isosteviol Sodium Injection on Acute Focal Cerebral Ischemia in Rats.
Topics: Animals; Antipyrine; Brain; Dose-Response Relationship, Drug; Edaravone; Edema; Immunohistochemistry | 2016 |
Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model.
Topics: Animals; Antipyrine; Bone Marrow Cells; Brain Ischemia; Chemokine CXCL12; Disease Models, Animal; Ed | 2016 |
Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice.
Topics: Animals; Antipyrine; Blood Pressure; Cell Death; Cerebral Infarction; Disease Models, Animal; Edarav | 2008 |
Bilateral middle cerebral artery infarctions following mild varicella infection: a case report.
Topics: Acyclovir; Antipyrine; Antiviral Agents; Chickenpox; Child, Preschool; DNA, Viral; Edaravone; Herpes | 2009 |
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
Topics: Animals; Antipyrine; Blood Pressure; Blotting, Western; Brain Ischemia; Cells, Cultured; Cerebral He | 2009 |
Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain.
Topics: Animals; Antipyrine; Basement Membrane; Brain Ischemia; Cerebral Hemorrhage; Edaravone; Free Radical | 2009 |
Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model.
Topics: Animals; Antipyrine; Biomarkers; Brain Ischemia; Cerebrovascular Circulation; DNA Damage; Edaravone; | 2009 |
Mapping selective neuronal loss and microglial activation in the salvaged neocortical penumbra in the rat.
Topics: Animals; Antipyrine; Autoradiography; Brain Mapping; Cerebrospinal Fluid; Cerebrovascular Circulatio | 2010 |
Repeated edaravone treatment reduces oxidative cell damage in rat brain induced by middle cerebral artery occlusion.
Topics: Animals; Antioxidants; Antipyrine; Biomarkers; Brain; Brain Ischemia; Edaravone; Free Radical Scaven | 2009 |
Effects of fentanyl pretreatment on regional cerebral blood flow in focal cerebral ischemia in rats.
Topics: Analgesics, Opioid; Animals; Antipyrine; Blood Flow Velocity; Carbon Radioisotopes; Cerebral Cortex; | 2010 |
A novel rodent model of reperfusion injury following occlusion of the middle cerebral artery.
Topics: Animals; Antipyrine; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship | 2010 |
Effects of GABA(A) receptor blockade on regional cerebral blood flow and blood-brain barrier disruption in focal cerebral ischemia.
Topics: Aminoisobutyric Acids; Animals; Antipyrine; Bicuculline; Blood-Brain Barrier; Brain Ischemia; Carbon | 2011 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
Topics: Acetates; Administration, Oral; Animals; Antipyrine; Atrophy; Behavior, Animal; Brain Injury, Chroni | 2011 |
In vivo optical imaging for evaluating the efficacy of edaravone after transient cerebral ischemia in mice.
Topics: Animals; Annexin A5; Antipyrine; Apoptosis; Autophagy; Blood-Brain Barrier; Blotting, Western; Cereb | 2011 |
Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress.
Topics: Animals; Antipyrine; Apoptosis; Caspase 12; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2012 |
Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury.
Topics: Analysis of Variance; Animals; Antipyrine; Bromodeoxyuridine; Cerebral Infarction; Cerebral Ventricl | 2012 |
Modifying neurorepair and neuroregenerative factors with tPA and edaravone after transient middle cerebral artery occlusion in rat brain.
Topics: Animals; Antipyrine; Brain; Chondroitin Sulfate Proteoglycans; Edaravone; Fibrinolytic Agents; Free | 2012 |
Kallikrein gene transfer induces angiogenesis and further improves regional cerebral blood flow in the early period after cerebral ischemia/reperfusion in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Carbon Isotopes; Cerebral Infarction; | 2012 |
Edaravone ameliorates oxidative stress associated cholinergic dysfunction and limits apoptotic response following focal cerebral ischemia in rat.
Topics: Animals; Antipyrine; Apoptosis; Basal Ganglia; Caspase 3; Choline O-Acetyltransferase; Cholinergic N | 2012 |
Protective effects of MCI-186 on transplantation of bone marrow stromal cells in rat ischemic stroke model.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antipyrine; Brain; Brain Infarction; Brain-Derived | 2012 |
Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger.
Topics: Animals; Antipyrine; Edaravone; Enzyme Inhibitors; Free Radical Scavengers; Infarction, Middle Cereb | 2003 |
Extension of cerebral hypoperfusion and ischaemic pathology beyond MCA territory after intraluminal filament occlusion in C57Bl/6J mice.
Topics: Analysis of Variance; Animals; Antipyrine; Autoradiography; Blood Pressure; Brain; Brain Ischemia; C | 2004 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
Topics: Acetates; Animals; Antipyrine; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Chromones; C | 2005 |
Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia.
Topics: Animals; Antipyrine; Brain Ischemia; DNA-Binding Proteins; Edaravone; Ethidium; Free Radical Scaveng | 2004 |
[A case of common carotid artery dissection showing remission in short-term].
Topics: Antipyrine; Aortic Dissection; Aspirin; Carotid Artery Diseases; Carotid Artery, Common; Drug Therap | 2005 |
Soluble epoxide hydrolase: a novel therapeutic target in stroke.
Topics: Adamantane; Animals; Antipyrine; Autoradiography; Blood-Brain Barrier; Blotting, Western; Capillarie | 2007 |
A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.
Topics: Animals; Antioxidants; Antipyrine; Benzenesulfonates; Blood Pressure; Brain Ischemia; Cell Death; Do | 2007 |
Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in rats.
Topics: Animals; Antipyrine; Body Weight; Brain Ischemia; Cerebrovascular Circulation; Diterpenes; Dose-Resp | 2008 |
Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations.
Topics: Animals; Antipyrine; Autoradiography; Brain Edema; Brain Ischemia; Cerebrovascular Circulation; Colo | 2001 |